The use of first and second-generation EGFR tyrosine kinase inhibitors (TKIs) has substantially improved the clinical outcomes of NSCLC patients with the classical sensitizing mutation (L858R or Ex19del) [2,3,4]. Here, EGFR is linked to non-small cell lung carcinoma.